Today 2026.05.16 D-118
Today 
|
Plenary Session 1 CAR T Cell Therapy Sep. 17 (Thu), 10:30-11:50 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Nack-Gyun Chung (College of Medicine, The Catholic University of Korea, Korea) | |
Current Real World Practice to Optimize Outcomes of CAR T Cell Therapy for Pediatric ALL
Children's Hospital of Philadelphia, USA
Eliminating GVHD Prophylaxis: A New Era of Sequential CAR-T and Allogeneic HSCT
The First Affiliated Hospital, Zhejiang University School of Medicine, China
|
Plenary Session 2 GVHD Sep. 17 (Thu), 13:00-14:20 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Hee-Je Kim (College of Medicine, The Catholic University of Korea, Korea) | |
Beyond Immunosuppression: Enhancing Tissue Resilience to Mitigate GVHD
Dan L. Duncan Comprehensive Cancer Center, USA
Immunologic Mechanisms and Modulation of Graft-Versus-Host Disease
University of Minnesota, USA
|
Joint Symposium 1 (ASTCT-KSBMT) Evolving T-cell Manipulation Strategies: Optimization of PTCy and New Frontiers in T Cell Depletion Sep. 17 (Thu), 14:30-16:00 |
Room A (1F) |
|
|---|---|---|
TBD
University of Minnesota, USA
TBD
Fred Hutchinson Cancer Center, USA
TBD
TBD, TBD
|
Scientific Session 1 Next-Generation Immune Effector Cell Therapies: Emerging Platforms and Biological Insights Sep. 17 (Thu), 14:30-16:00 |
Room B (1F) |
|
|---|---|---|
| Chair(s) |
Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea) Deok Hwan Yang (Chonnam National University Medical School, Korea) |
|
Biomarkers and Immune Fitness Shaping Outcomes of Immune Effector Cell Therapies
Dana-Farber Cancer Institute, USA
In Vivo CAR-T Engineering for Lymphoid Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
Overcoming Resistance in T-cell Malignancies: From Phase 1 Study of CD5-targeted Allogeneic CAR-NK Cells
University of Ulsan College of Medicine, Korea
|
Scientific Session 2 Advances in Immunotherapy and Transplant Strategies in Pediatric Hematologic Malignancies Sep. 17 (Thu), 14:30-16:00 |
Room C (2F) |
|
|---|---|---|
| Chair(s) |
Keon Hee Yoo (Sungkyunkwan University School of Medicine, Korea) Jun Eun Park (Korea University College of Medicine, Korea) |
|
Virus-specific T Cells for Adoptive Immunotherapy
Dana-Farber Cancer Institute, USA
Strategies for Determining Treatment Flow of CAR T-Cell Therapy and HSCT in Pediatric ALL
Wroclaw Medical University, Poland
TBD
Sungkyunkwan University School of Medicine, Korea
|
Education Session 1 Additional Cellular Support after Allogeneic Transplantation Sep. 17 (Thu), 14:30-16:00 |
Room D (2F) |
|
|---|---|---|
| Chair(s) | Hyoung Soo Choi (Seoul National University College of Medicine, Korea) | |
Management of Poor Graft Function in Chilren
Korea University College of Medicine, Korea
Donor Lymphocyte Infusion (DLI) in 2026: Indications, Dosing, and GVHD Trade-offs
University of Ulsan College of Medicine, Korea
Cellular Support Beyond the Graft: Integrative Strategis after Allogeneic HSCT
Case Western Reserve University School of Medicine, USA
|
Joint Symposium 2 (EBMT-KSBMT) Evolving Donor Issues in Allogeneic HSCT: From HLA Matching to Germline Screening and Emerging Concerns Sep. 17 (Thu), 16:50-18:30 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Ibrahim Yakoub-Agha (Lille University Hospital, France) | |
TBD
University of Tor Vergata, Italy
Which Donor Should We Use in the Absence of a Matched Sibling?
La Fe University and Polytechnic Hospital, Spain
TBD
TBD, TBD
TBD
TBD, TBD
|
Scientific Session 3 Post-Transplant Residual Disease in Acute Leukemia: Monitoring and Therapeutic Strategies Sep. 17 (Thu), 16:50-18:20 |
Room B (1F) |
|
|---|---|---|
| Chair(s) |
Myungshin Kim (The Catholic University of Korea, Korea) Ho-Jin Shin (Pusan National University School of Medicine, Korea) |
|
Flow Cytometric MRD for AML: Updates in 2026
Amsterdam UMC, The Netherlands
Targeting Residual Disease after Transplant: The Convergence of HSCT and Engineered Cellular Therapies
Columbia University Irving Medical Center, USA
Clinical Experience with NGS-based Chimerism Analyses in HSCT Patients
Yonsei University College of Medicine, Korea
|
Scientific Session 4 Science Behind Treatment Response and Relapse Sep. 17 (Thu), 16:50-18:20 |
Room C (2F) |
|
|---|---|---|
| Chair(s) |
Je-Hwan Lee (University of Ulsan College of Medicine, Korea) Sung-Soo Yoon (Seoul National University College of Medicine, Korea) |
|
Longitudinal Single-Cell Dissection of Venetoclax Resistance in Secondary AML
UNIST, Korea
Mechanism of Immune Evasion in AML
Vanderbilt University Medical Center, USA
Immune Escape as a Mechanism of Post-transplant Relapse
Taussig Cancer Institute, USA
|
Joint Symposium 3 (East Asia Collaborative Session) The CAR-T Landscape in East Asia: Approvals, Coverage, Domestic Development, and Regulatory Frameworks for Cell Therapy Sep. 18 (Fri), 10:10-11:50 |
Room A (1F) |
|
|---|---|---|
Insights into the Development of Cellular Therapy in China: Current Landscape and Future Directions
National Clinical Research Center for Hematologic Disease, China
TBD
TBD, TBD
TBD
TBD, TBD
TBD
TBD, TBD
|
Scientific Session 5 AML/MDS Biology Sep. 18 (Fri), 10:10-11:40 |
Room B (1F) |
|
|---|---|---|
| Chair(s) |
Jae-Sook Ahn (Chonnam National University Medical School, Korea) Chul Won Jung (Sungkyunkwan University School of Medicine, Korea) |
|
Stem Cell Regulation in AML
New York University Grossman School of Medicine, USA
Genomics for Precision Prediction of Treatment Response and Resistance in AML
Moffitt Cancer Center & Research Institute, USA
Information-driven Studeis on AML
College of Pharmacy, Seoul National University, Korea
|
Scientific Session 6 Potential Role of AI in Hematology and Cellular Therapy Sep. 18 (Fri), 10:10-11:40 |
Room C (2F) |
|
|---|---|---|
| Chair(s) |
Yoo Jin Kim (College of Medicine, The Catholic University of Korea, Korea) Jae-Yong Kwak (Jeonbuk National University Medical School, Korea) |
|
AI-Driven Prediction of Transplant Outcomes
University Hospital Essen, Germany
AI-Based Prediction of Early Relapse after CAR-T Therapy
University of California, San Francisco, USA
Clinical Relevance of BM fibrosis in MDS Using Digital Imaging Approaches
Seoul National University College of Medicine, Korea
|
Education Session 2 Toxicities of Transplant and Immunotherapy Sep. 18 (Fri), 10:10-11:40 |
Room D (2F) |
|
|---|---|---|
| Chair(s) |
Hyoung Jin Kang (Seoul National University College of Medicine, Korea) Hyeon Jin Park (National Cancer Center, Korea) |
|
Autoimmune Cytopenia and Pure Red Cell Aplasia after HSCT
Seoul National University College of Medicine, Korea
Best Anti-fungal Prophylaxis and Treatment pre-/post-HSCT
The Catholic University of Korea, Korea
Real World Management of CAR T Cell Toxicities-expert Opinion
Children's Hospital of Philadelphia, USA
|
Joint Symposium 4 (ISCT-KSBMT) Non-CAR T Cell Immunotherapy Sep. 18 (Fri), 13:00-14:30 |
Room A (1F) |
|
|---|---|---|
TBD
TBD, TBD
TBD
TBD, TBD
TBD
TBD, TBD
|
Scientific Session 7 Expanding CAR T-Cell Therapy beyond Lymphoid Malignancies: Myeloid Neoplasms, Solid Tumors, and Autoimmune Diseases Sep. 18 (Fri), 13:00-14:30 |
Room B (1F) |
|
|---|---|---|
| Chair(s) |
June-Won Cheong (Yonsei University College of Medicine, Korea) Sung-Hyun Kim (Dong-A University College of Medicine, Korea) |
|
Overcoming Barriers in CAR T - Cell Therapy for AML through Cytokine-armored CAR Design
Memorial Sloan Kettering Cancer Center, USA
Next-generation Switchable CAR-T Platform: Enhancing Precision and Efficacy in Solid Tumors
Seoul National University College of Medicine, Korea
Deep B Cell Depletion beyond Hematology: Immune Reset as a New Treatment Paradigm for Autoimmune Diseases
Erlangen-Nürnberg, Germany
|
Education Session 3 Practical Issues in Stem Cell Transplantation 2026 Sep. 18 (Fri), 13:00-14:30 |
Room D (2F) |
|
|---|---|---|
| Chair(s) |
Kyoung Ha Kim (Soonchunhyang University College of Medicine, Korea) Yong Park (Korea University College of Medicine, Korea) |
|
Recent Trends in Conditioning Regimens for Myeloid Malignancies
Chungnam National University College of Medicine, Korea
PTCy as a Universal Platform for GVHD Prophylaxis: Integrating New Standards and Defining the Remaining Role of ATG
Gregorio Marañón University General Hospital, Spain
Adult Cord Blood Transplantation Program for New Centers: A Practical Institutional Guide
Seoul National University College of Medicine, Korea
|
Presidential Symposium Lymphoma Cell Therapy Sep. 18 (Fri), 14:40-15:20 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Hyeon-Seok Eom (National Cancer Center, Korea) | |
Evolution of Cellular Therapies in Management of Lymphoma Patients
University of Pennsylvania, USA
|
Plenary Session 3 HSCT for Non-Malignant Disease Sep. 18 (Fri), 15:20-16:00 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Ho Joon Im (University of Ulsan College of Medicine, Korea) | |
Management of Mixed Chimerism and Graft Failure in Non-malignant Diseases
Dana-Farber Cancer Institute, USA
|
Debate Session 1 KOR Allogeneic HSCT in Patients with AML or MDS with TP53 Alternation Sep. 18 (Fri), 15:20-16:00 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Joon Ho Moon (Kyungpook National University School of Medicine, Korea) | |
To Transplant
Chonnam National University Medical School, Korea
Not to Transplant
Yonsei University College of Medicine, Korea
|
Debate Session 2 KOR HSCT for HLH: Decreased Conditioning Intensity vs. Increased Conditioning Intensity Sep. 18 (Fri), 17:30-18:20 |
Room A (1F) |
|
|---|---|---|
| Chair(s) | Kyung-Nam Koh (University of Ulsan College of Medicine, Korea) | |
Reduced Intensity Conditioning
University of Ulsan College of Medicine, Korea
Myeloablative Conditioning
Chonnam National University Medical School, Korea
|
Joint Symposium 5 (JSTCT-KSBMT) EBV-Associated Diseases and HSCT: From CAEBV to Post-Transplant Complications Sep. 18 (Fri), 16:50-18:30 |
Room C (2F) |
|
|---|---|---|
TBD
TBD, TBD
TBD
TBD, TBD
TBD
TBD, TBD
TBD
TBD, TBD
|
Scientific Session 8 Advances in HSCT Conditioning Sep. 18 (Fri), 16:50-18:20 |
Room D (2F) |
|
|---|---|---|
| Chair(s) |
Seong Kyu Park (Soonchunhyang University College of Medicine, Korea) Sang Kyun Sohn (Kyungpook National University School of Medicine, Korea) |
|
Optimal Conditioning in Allogeneic HSCT
Fred Hutchinson Cancer Center, USA
Allogeneic Hematopoietic Cell Donor Selection in 2026
Memorial Sloan Kettering Cancer Center, USA
Optimal Conditioning in Autologous HSCT
Seoul National University College of Medicine, Korea
|
Joint Symposium 6 (TSBMT-KSBMT) Endothelial Injury after HSCT: Cutting-Edge Science and Real-World Practice in Türkiye and Korea Sep. 19 (Sat), 09:00-10:00 |
Room A (1F) |
|
|---|---|---|
TBD
TBD, TBD
TBD
TBD, TBD
|
Scientific Session 9 Insights on GVHD Prediction, Prevention and Management Sep. 19 (Sat), 10:10-11:40 |
Room A (1F) |
|
|---|---|---|
| Chair(s) |
Hoon Kook (Chonnam National University Medical School, Korea) Byung Sik Cho (College of Medicine, The Catholic University of Korea, Korea) |
|
Pediatric Chronic GVHD: From Biological Insights to Clinical Management
BC Children's Hospital Research Insitutue, Canada
Immunobiology of GVHD Prevention
Hokkaido University, Japan
Microbiome and GvHD Following Allogeneic HSCT
University of Ulsan College of Medicine, Korea
|
Scientific Session 10 Immune Effector Cell Therapy in Lymphoid Malignancies: From Pivotal Trials to Real-World Practice Sep. 19 (Sat), 10:10-11:40 |
Room C (2F) |
|
|---|---|---|
| Chair(s) |
Jin Seok Kim (Yonsei University College of Medicine, Korea) Young Rok Do (Keimyung University School of Medicine, Korea) |
|
Integrating MRD into CAR T-cell Therapy for ALL: from Patient Selection to Post-treatment Intervention
Memorial Sloan Kettering Cancer Center, USA
Sequencing Cellular Therapy in Multiple Myeloma: Lessons from Trials and Real-world Practice
Medical College of Wisconsin, USA
Real-world CAR‑T Experience in LBCL
The Catholic University of Korea, Korea
